Skip to content
Peptide research

Pancragen

Category
Bioregulators
Administration routes
InjectableOral
Regulatory status
Not FDA-approved

What it is

A synthetic tetrapeptide marketed to support pancreatic function and blood sugar control in aging adults. Human evidence is weak, limited to small elderly-diabetic studies showing modest glucose drops, while cell-regeneration claims rest on animal and mechanism-only research. Safety data is minimal, and combining it with diabetes drugs risks hypoglycemia. Supply is mostly unregulated research-grade product, and it is not an approved drug in the US.

Read Full record

Studied uses & evidence

Studied uses(5)

  • Correction of impaired glucose tolerance in aging

    Low

    Metabolic effects were reported in aged monkeys and small human studies; independent confirmation was not identified in the reviewed evidence.

  • Reduction of fasting glucose and insulin resistance in elderly diabetic patients

    Low

    Small human reports suggest glucose-lowering effects; robust independent confirmation was not identified in the reviewed evidence.

  • Stimulation of pancreatic cell differentiation and anti-aging gene expression

    Low

    Consistent cell-culture data from one lab group, mechanism-supported, no independent confirmation.

Evidence limits

Evidence Level
Limited Evidence

The clinical evidence for Pancragen is limited but internally consistent. The strongest human evidence comes from a single clinical study (Korkushko et al. 2011) in 63 elderly subjects showing that Pancragen significantly reduced fasting glucose, improved glucose tolerance, and lowered insulin resistance in type 2 diabetic patients. This was not a randomized, double-blind, placebo-controlled trial by modern Western standards. Two non-human primate studies in aged rhesus monkeys (Goncharova et al. 2014, 2015) provide the strongest preclinical evidence, demonstrating normalization of insulin dynamics and glucose tolerance with effects persisting after treatment cessation. In vitro studies confirm molecular mechanisms (gene expression modulation, epigenetic remodeling). The major limitations are: single research group origin, small sample sizes, lack of independent replication, and absence of formal clinical development outside Russia.

Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)

Cautions & risk summary

General cautions

  • Pregnancy or breastfeeding

    Absolute

    No human reproductive safety data exists for this peptide. Effects on fetal development are unknown.

  • Children under 18

    Absolute

    No pediatric safety data. Not recommended for use in minors.

  • Known hypersensitivity

    Absolute

    Discontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).

Risk summary(5)

Risks = level of concern: High · Moderate · Low · Theoretical

  • Limited safety data and lack of independent validation

    High
  • Hypoglycemia risk when combined with diabetes medications

    Moderate
  • Unregulated product quality (research-grade sources)

    High
  • Individual intolerance or allergic reaction

    Low
  • Contraindicated in pregnancy and lactation

    Moderate
Safety & interactions in Full record

Further reading

Read Full record

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.